Trial demonstrates 86% union rate in long bone fractures with ADSCs and platelet-rich plasma, suggesting effectiveness over BMAC.
Background Non-union is a common clinical complication that causes serious limb debilities and eventually leads to permanent limb impairments if not treated on time. This proof-of-concept study was undertaken to evaluate the osteogenic potential of autologous adipose derived stromal cells (ADSCs) in long bone non-unionadipose-derived stromal cells (ADSCs) in long-bone nonunion. Methods: Seven patients with long-standing atrophic non-union of long bones were treated with percutaneous implantation of a minimum of 100 million ADSC and platelet-rich plasma containing a minimum of 10 billion platelets into the non-union site of long bones under fluoroscopic guidance. Besides radiological imaging for evidence of consolidation, patients were also followed up for clinical parameters, standard lower extremity functional scale (LEFS) and SF12 scores. The patients were followed for a minimum of one year, & Intervention was considered a failure if no evidence of healing was observed up to 6 months post-procedure Results: We observed union in 6 of 7 (86%) patients within 4 months after the procedure. The first evidence of healing was visible within 8 weeks after treatment in five (71%) patients. Conclusions: The study demonstrated the efficacy of ADSCs as a better alternative to bone marrow aspirate concentrate (BMAC) in treating long bone non-union. Level of Evidence Level 3 Trial Registration: This study has been registered in the US Clinical Trial Registry (U.S. National Library of Medicine) with Trial registration no. NCT04340284 . Titled as Adipose Derived Stromal Vascular Fraction (SVF) Application in treatment of Long Bone nonunion https://clinicaltrials.gov/ct2/show/ NCT04340284 ?term=NCT04340284&draw=2&rank=1 Date of registration 09/04/2020 Keywords: Non-union, long bone fracture, Bone Marrow Aspirate Concentrate (BMAC), Adipose derived stromal cells (ADSCs), mesenchymal stem cells, Growth stimulators, Platelet Rich Plasma (PRP).
No takes yet. Share an insight, caveat, or question.
Bansal et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: